A

PROJECT REPORT

ON

AN EMPIRICAL STUDY ON INFLUENCE OF

ECONOMIC VARIABLES OF CRYPTOCURRENCY "SHIBA INU"
PROJECT REPORT SUBMITTED IN PARTIAL FULFILLMENT FOR THE
AWARD OF THE DEGREE OF

MASTER OF BUSINESS ADMINISTRATION

SUBMITTED

BY

MD ABDUL HAKEEM

HALL TICKET NO. : 140221672156

UNDER THE GUIDANCE OF

PROF. VINODHINI
(ASSOCIATE PROFESSOR)

DEPARTMENT OF BUSINESS MANAGEMENT

AMJAD ALI KHAN COLLEGE OF BUSINESS

ADMINISTRATION (Affiliated to Osmania University)
Mount Pleasant, 8-2-249 to 267, BANJARA Hills Rd Number 3, Hyderabad,
 Telangana - 500034, India (2021
– 2023)

DR. LAKSHMI RAWAT Office: “Mount Pleasant” DIRECTOR #8-2-249,RoadNo.3,BanjaraHills,

Hyderabad – 500034,
: 040-23280241 / 040-2328024
Fax: 040-23280786,
E-mail:professorshehbaz@[Link]
[Link]@[Link]
Website: [Link]

CERTIFICATE

This is to certify that the project report titled AN EMPIRICAL STUDY ON

INFLUENCE OF ECONOMIC VARIABLES OF CRYPTOCURRENCY
“SHIBA INU", submitted in partial fulfilment for the award of MBA program of
Department Of Business

Management, O.U., Hyderabad, was carried out by MD ABDUL HAKEEM bearing

the HT. NO. 140221672156 student of MBA (SYSTEMS). This has not been submitted to any other

university or institution for the award of any degree /diploma / certificate.

DR. LAKSHMI RAWAT DIRECTOR

 Office: “Mount Pleasant”
#8-2-249,RoadNo.3,BanjaraHills,
Prof. VINODHINI Hyderabad – 500034,
ASSOCIATE PROFESSOR : 040-23280241 / 040-2328024
Fax: 040-23280786, E-
mail:raghaveni.t@[Link]
Website: [Link]
CERTIFICATE

This is to certify that the project report titled AN EMPIRICAL STUDY ON

INFLUENCE OF ECONOMIC VARIABLES OF CRYPTOCURRENCY
“SHIBA INU”, submitted in partial fulfilment for the award of MBA program of
Department Of Business

Management, O.U., Hyderabad, was carried out by MD ABDUL HAKEEM bearing

the HT. NO. 140221672156 student of MBA (SYSTEMS) under my guidance. This
has not been submitted to any other university or institution for the award
of any degree / diploma / certificate.

Prof. VINODHINI

ASSOCIATE PROFESSOR
 DECLARATION
I hereby declare that this project report titled a study on “EMPIRICAL STUDY ON
INFLUENCE OF ECONOMIC VARIABLES OF CRYPTOCURRENCY SHIBA
INU ” submitted by me to the department of MASTER OF BUSINESS ADMINISTRATION
(Osmania University), is a record of bonafide work undertaken by me.

To the best of my knowledge and belief, this project is not submitted to any other

University or Institution for the award of any degree or any diploma/ certificate or

published any time before.

SYED EHTESHAMUDDIN
DANISH
HALL TICKET NO: 140220672135
. ACKNOWLEDGEMENT

I would like to give special acknowledgement to Dr. LAKSHMI RAWAT

DIRECTOR, AMJAD ALI KHAN COLLEGE OF BUSINESS

ADMINISTRATION (Affiliated to Osmania University) HYDERABAD,

for his consistent support and motivation.

I am grateful to prof. VINODHINI, ASSOCIATE PROFESSOR, AMJAD ALI

KHAN COLLEGE OF BUSINESS ADMINISTRATION (Affiliated to Osmania

university) HYDERABAD, for her technical expertise, advice, and excellent guidance.
she not only gave my project a scrupulous critical reading but added many examples and

ideas to improve it.

I would like to express my appreciation towards my friends for their encouragement and

support throughout this project.

MD ABDUL HAKEEM
HALL TICKET NO: 140221672156
 TABLE OF CONTENTS
[Link] DESCRIPTION PAGE NOS

CHAPTER-1 1.1 INTRODUCTION 2-3

1.2 NEED OF THE STUDY 4
1.3 OBJECTIVES 5
1.4 HYPOTHESIS 5
1.5 RESEARCH METHODOLOGY 5-7

CHAPTER-2 LITREATURE REVIEW 8-14

CHAPTER-3 INDUSTRY PROFILE 16-20

COMPANY PROFILE 21-24

CHAPTER-4 DATA ANALYSIS AND 26-42

INTERPRETATION

CHAPTER-5 FINDING, SUGGESTION AND 44-46

CONCLUSION
BIBILOGRAPHY 47

CHAPTER-1
 INTRODUCTION

1.1 INTRODUCTION:

As per the data of research firm IQVIA, India sold nearly 7.5 crore strips of Dolo tablets

before the COVID-19 outbreak in 2019. The first wave of the pandemic started in India

around March

2020, whereas the devastating second wave, which registered most deaths, hit the country in

May 2021. With the overall cases accounting for more than 3.5 crore, over 350 crore tablets

of Dolo were sold in 2020 and 2021. Dolo is currently the second most sold anti-fever and

analgesic tablet in India with a turnover of Rs 307 crore last year, whereas GSK's Calpol is

just a notch above it with a turnover of Rs 310 crore. Crocin is the sixth-largest in this

category, with double-digits sales of Rs 26.3 crores.

Due to covid-19 third wave, Dolo, a paracetamol brand from Bengaluru-based micro labs

turned India’s highest selling medicine brand revenue in January, along with GSK’s

antibiotics Augmentin. Both brands had revenue of Rs57 crore each in the month.

For the last 12 months period (moving annul total or MAT) that includes January 2022. Dolo

was the ninth position with the sales of Rs 474 crore. Augmentin, which in the third position,

had garnered Rs 599 crore.

1
Its sales peaked during the second wave as it sold Rs 49 crore worth of tablets in April 2021,

the highest monthly sales ever made as per the data from healthcare research firm IQVIA.

People on the internet have gone as far as calling it India's national tablet and favourite snack.

Dolo 650 was awarded as the best-managed brand of the year and recognized as India's most

admired brand.

The paracetamol market is poised to grow at CAGR of 4.3% during the forecast period

20222027.

Easy availability and being the doctors preferred prescription during the second wave among

the reasons that have fueled the rise in sales of dolo-650, a brand of paracetamol. To be sure,

there was a sale of all brands of paracetamol as it is the safest medicine for fever that was

prescribed to almost everyone with Covid-19.

The total revenue generated by paracetamol increased by 138.45 per cent between the second

quarter of 2021, when India was witnessing the second wave of the pandemic, the revenue

generated by dolo-650 increased by 289.6 percent in the same period.

The supply chain of crocin hasn’t been regular through the pandemic there are periods when

it is not readily available. The other alternative is Calpol, but it costs more than Dolo. This is

the reason Dolo becomes popular during the pandemic.

There has been an increase in sales of all antipyretic medicine. It is an over-the-counter pill

and the people are buying and having it. Dolo just managed to cultivate its brand, especially

among the doctors, in the early days of the pandemic and it’s reaping the benefits.

As India effected with the third wave of covid, Dolo-650 which has clocked sales of Rs 5.7

billion during the pandemic since march 2020 and topped the chart of paracetamol pill has

been dubbed as a “favorite snack”. Dolo is now currently the second most popular anti- fever

2
and analgesic tablet in India, with a turnover of 3.1 billion in 2021, only ahead of GSK’s

capital, which has a turnover of 3.1 billion.

1.2 NEED OF THE STUDY:

• To allocate resources for future growth and manage its cash flow.
• It helps business to estimate their costs and revenue accurately based on which they
are able to predict their short-term and long-term performance.

• It helps in guiding marketing, production and other business activities for achieving
these targets.

• Operations develop and uses forecasts for scheduling, inventory management, and
long-term capacity planning.

• It helps to determine the production capacity that is actually required.

3
1.3 OBJECTIVES:
• To evaluate the sales forecast of dolo medicine at the time of COVID.

• How it became the market leader during pandemic.

• How it has benefited the manufactures.

1.4 HYPOTHESIS:

Ho: There is no significant difference in sales during pandemic.

H1: There is significant difference in sales during pandemic.

HA: There is an average difference in sales during pandemic

1.5 RESEARCH METHODOLOGY:

1.5.1 SCOPE:

• To understand the sales performance of Dolo medicine during pandemic.

• To understand how it become the market leader in paracetamol medicine.

• To study the market strategy of Dolo medicine making huge profits after covid-19.
• To study the pre covid-19 and post covid-19 sale of Dolo medicine.

4
1.5.2 REGRESSION ANALYSIS:

Regression analysis widely used statistical method to estimate the relationship between on or

more independent variable and dependent variables. Regression is a powerful tool as it used

to assess the strength of the relationship between two or more variables, and then it would be

used for modelling the relationship between those variables in the feature.

Linear regression equation:

Linear analysis is one type of regression analysis. Dependent variable in the formula which is

one is trying to predict what will be the feature value.

𝛴𝑥𝑦−𝑛𝑥̅𝑦̅
𝑏= ∑ 𝑥2−𝑛(𝑥̅)2 _____________ (1)

To find the linear trend component for the sales

y = a + bx _________________ (2) To find the

slope(b) of the line a =Y –bX

_________________ (3)

1.5.3 SOURCE OF INFORMATION:

The data is secondary. which is collected through Micro labs limited web site. This data is

collected for the sales estimation of the dolo medicine during pandemic it become the market

leader during COVID 19. So, to compare the sales independent variable, like the number of

sales calls. then we have collected the data from seasonal sales and the total sales calls for the

last 2 years between 2019-2020.

5
1.5.4 TOOLS AND TECHNIQUE OF ANALYSIS:

• In this study descriptive analytics is [Link] drawing conclusion from large, raw

datasets. The findings and the visualized in to accessible lines graph, tables, pie

and bar charts, and generated [Link] using statistical analysis tools excel

and R studio.

CHAPTER-2
LITREATURE REVIEW
This literature review is based on sales forecast of Dolo medicine before and after

[Link] was conducted using an explorative and un constructed data of review on project

which explored the sales of Dolo medicine during the COVID-19 pandemic by studying the

news and articles that offered different insight and perspective. The purpose of the review to

identify the sales of Dolo medicine during the years 2019-2021.

Literature review:

There are 3 major reasons for becoming the market leader.

6
 • During the first and second wave the vaccination process is very slow. Then

doctors are decided to give some temporary reliefs from the symptoms like cold,

cough and [Link] they decided to give medicine like paracetamol. But some

weird reason out of all paracetamol selling brands doctors have prescribed Dolo

650 medicine during the COVID-19 pandemic. According to Chiru Goel

Sachdeva, HOD and Consultant-Internal Medicine, Manipal Dwarka Hospital in

New Delhi, Dolo 650 is basically a paracetamol drug.

Why Dolo 650? By some literatures said that it is a Dolo medicine manufacture Micro labs

limited marketing strategy.

• For any chemical there is an optimum concentration in peak of effectiveness.

Basically, anything above or below this concentration is comparatively less

effective. Bhupendra Kumar, general secretary of the Indian Pharmacist

Association, said, “Crocin and Dolo are the most commonly prescribed brands of

paracetamol. However, Crocin is more readily available in a 500 mg formulation

whereas Dolo is available in a 650 mg formulation. Since people were getting

high fever during the second wave, many doctors were prescribing Dolo.

• Third and main reason is less bowel irritation. Many times, patient suffer from

bowel irritation. But in Dolo 650 it has not the optimum concentration nor the

effective concentration. So, it is less effective on bowel irritation and make the

people perception that this drug is better than other drugs in the market. According

to Ravi Shekhar Jha, Additional Director and Head, Pulmonology, Fortis Escorts

Hospital, Faridabad, the safety profile of Dolo is good and it is not very costly

either.

7
Apart from these valid reasons there is one reason for any necessary unnecessary thing in

making sensationalize i.e., social media marketing. According to The Indian Express, dolo

fever strikes memes as the third waves drives up paracetamol sales.

On platform like twitter from 26 January to 27 January evening nearly 100s of memes are

tweeted like #dolo650 and their total reach around the world was 14355862. Aviral

Bhatnagar, an investor at Venture Highway which is an early-stage seed fund, said in a tweet

on Thursday: "Dolo 650 is a sleeper hit: 3.5B pills sold in pandemic, 600 Cr of sales with one

drug, used for treating virtually everything, brand name equal to paracetamol, manufacturer

Micro Labs doing 2,700 Cr of revenue.

From the article, micro labs where excellence lies in the small tails. Established in 1973.

Micro labs limited is a multi-faceted health care organization with a proficient marketing

team, stateof-the- art manufacturer facilities and R&D centres that are at par with

international standards.

Dr SP Kalantari, professor of medicine, mahatma Gandhi institute of medical sciences,

Maharashtra, believes it could be a mix of everything, including good luck, behind Dolo’s

fame. He said that “workhorse painkiller” merely comforts the patients when their distress

level is high.

As per the data from health care research firm IQVIA, India sold nearly 7.5 crore strips of

dolo –a paracetamol tablet manufactured by Bengaluru-based micro labs Ltd -before the

covid outbreak in 2019.

India has sold more than 350 crore Dolo tablets, becoming the second most consumed

antifever and analgesic tablet in the country, only behind GSK’s Calpol. The annual sales of

Dolo medicine have plummeted from 9.4 crore strips or 141 crore tablets in 2019 to 14.5

crore strips or 217 crore tablets by November 2021. The rising popularity of Dolo even made

8
the brand fodder for memes on the internet, wherein the medicine was called “India’s national

tablet or favourite snack.”

As the Omicron wave continues to gain a stronghold, the market share of the pill in the

650mg category is skyrocketing, shooting up from 52% in Jan 2021 to 57% in December

2021. Despite being a 30-year-old brand, Dolo has become a household name of great utility

and ubiquity. The oval-shaped pill is designed to ensure easy swallowability with the right

excipients, substances formulated alongside the active ingredients. Manufactured by Micro

Labs Ltd., Dolo 650 tablet sales have garnered INR 567 crore since March 2020.

Mechanism of Dolo 650:

Dolo 650 contains acetaminophen that belongs to aniline analgesics. The antipyretic action of

the drug is achieved by inhibiting the production of certain chemicals (prostaglandins) in the

body and increasing heat loss from the body. The tablet also stops the transmission of pain

signals to the brain, which reduces the pain experienced by the person.

Dolo 650 does not belong to non-steroidal anti-inflammatory drugs, and hence it is not

effective against inflammation. Since the side effects of Dolo 650 are rare, it is considered

safe as the first-line treatment for fever. Dolo starts action within an hour of administration,

and its effect lasts around 4 to 6 hours.

What made Dolo Popular Among Masses?

Unique Brand Positioning
While the market was flooded with paracetamol 500, there was no player in the paracetamol

650 segment until Micro Labs made its entry with Dolo 650 in 1973. The company identified

the space between normal fever and high fever and started encashing on the clinical evidence

that 650 mg provides superior relief.

Dolo consists of the same kind of generic salt as found in other anti-fever drugs like Crocin or

Calpol, but the manufacturer’s strategy to render the drug effective for ‘Fever of Unknown

9
Origin (FUO)’ as a part of their brand promotion increased the trustworthiness of the drug for

Covid among Indians. Some may attribute the success of Dolo to its relatively simple name,

compared to other drugs in the market for cold, flu, and fever.

Indirect Promotion

The indirect promotion of Dolo through memes and posts on social media platforms turned

out to be quite significant for the drug sales. However, the promotion and advertising of any

prescription drug is in violation of the Drugs and Magic Remedies Act. Being a favourite

among healthcare professionals, Dolo-650 has always remained the number one paracetamol

650 mg brand prescribed in India for decades. However, since doctors were not seeing

patients personally during the lockdown period, the prescriptions of Dolo-650 started floating

on WhatsApp, SMS, and voice messages, and word-of-mouth led to its immense popularity

among families across the country.

Vaccination Drive

After introducing COVID-19 vaccines such as COVAX in and Covi shield, the government

inoculated the biggest vaccination drive to immune the population. However, people started

experiencing symptoms like fever and body ache after taking the vaccine, which further

accelerated the intake of Dolo-650. The brand helped in enhancing awareness for vaccines by

addressing doubts through posters that answered the Frequently Asked Questions about

vaccines. These posters, available in English and local languages, helped popularize the brand

at the grassroots level. Additionally, the brand reached out to healthcare professionals and

provided a sample of Dolo-650, masks, and sanitizers for recommending the drug to people if

they got fever and pain post vaccination.

10
Safer Alternative

One of the key reasons behind the widespread adoption of Dolo 650 is that the drug is

timetested and suitable for people of all ages. The medication has minimal side effects and is

even safe for those suffering from cardiovascular disorders, renal diseases, or diabetes.

SALES OF DOLO-650 BEFORE AND AFTER COVID-19

2019 2021

MONTHS PROFIT MONTHS PROFIT

11
 January 7.5 crores January 15.9 crores

February 8.2 crores February 16.4 crores

March 11.7 crores March 19.4 crores

April 9.5 crores April 48.4 crores

May 6.1 crores May 44.2 crores

June 9.9 crores June 19.9 crores

July 5.4 crores July 24.3 crores

August 12.2 crores August 40.7 crores

September 10.1 crores September 41 crores

October 8.9 crores October 34.0 crores

November 13.9 crores November 33.4 crores

December 14.1 crores December 28.9 crores

Its sales peaked during the second wave as it sold Rs 49 crore worth of tablets in April 2021,

the highest monthly sales ever made as per the data from healthcare research firm IQVIA.

People on the internet have gone as far as calling it India's national tablet and favorite snack.

In 2019, the sales of all brands under the paracetamol category were nearly Rs 530 crore.

They touched Rs 924 crore by 2021. Dolo is India's second most sold anti-fever and analgesic
tablet, with a turnover of Rs 307 crore (in 2021). Crocin is the sixth-largest, with sales of Rs

23.6 crore.

• According to Charu Goel Sachdeva, HOD and Consultant-Internal Medicine, Manipal

Dwarka Hospital in New Delhi, Dolo 650 is basically a paracetamol drug.

12
• According to Ravi Shekhar Jha, Additional Director and Head, Pulmonology, Fortis

Escorts Hospital, Faridabad, the safety profile of Dolo is good and it is not very costly

either.

• Aviral Bhatnagar, an investor at Venture Highway which is an early-stage seed fund,

said in a tweet on Thursday: "Dolo 650 is a sleeper hit: 3.5B pills sold in pandemic,

600 Cr of sales with one drug, used for treating virtually everything, brand name equal

to paracetamol, manufacturer Micro Labs doing 2,700 Cr of revenue.

• Bhupendra Kumar, general secretary of the Indian Pharmacist Association, said,

“Crocin and Dolo are the most commonly prescribed brands of paracetamol.

However, Crocin is more readily available in a 500 mg formulation whereas Dolo is

available in a 650 mg formulation. Since people were getting high fever during the

second wave, many doctors were prescribing Dolo.”

13
 CHAPTER -3
INDUSTRY PROFILE AND
COMPANY PROFILE
3.1 INDUSTRY PROFILE
3.1.1 PHARMACEUTICAL INDUSTRY
The pharmaceutical industry has begun from Gupta period which was existed from

approximately 320 to 550 CE where people were dependent only on indigenous forms

medicines before British rule.

The department of pharmaceuticals was created on the 1 st July, 2008 by the ministry of

chemicals & fertilizers with the objectives to give greater focus and thrust on the

development of pharmaceuticals sector in the country and to regulate various complex issues

related to pricing and availability of medicines at affordable prices research & development,

protection of intellectual properties rights and international commitments related to

pharmaceuticals sector which requires coordination with other ministries.

The Indian pharmaceutical industry is the world’s 3 rd largest volume and 14th largest in terms

in value. The total annual turnover of pharmaceuticals was Rs 2,89,998 crore for the year

20192020. Total pharmaceuticals exports and imports were to the tune of 1,46,260 crore and

Rs 12,943 crore respectively in the year 2019-20.

Major segments of pharmaceuticals industry are generic drugs, OTC medicines and API/bulk,

drugs, vaccine, contract research and manufacturing, biosimilar and biologics.

India is the largest provider of generic drugs globally. Access to the affordable HIV

treatments from India is one of the greatest success stories in medicines. India is one of the

biggest suppliers of low-cost vaccine in the world. Because of low price and high quality,

Indian medicines are preferred worldwide. Thereby rightly making of the country the

14
“pharmacy of the world”. Pharma sector currently contributes to around 1.72% of the

country’s GDP.

India’s pharmaceuticals sector forms a major component of the country’s foreign trade, with

attractive avenues and opportunities for investors. India supplies affordable and low-cost

generic drugs to the millions of people across globe and operate the significant number of

united states food and drug administration (USFDA) and world health organization (WHO)

good manufacturing process (GMP) compliant plants. India has occupied a premier position

among the pharmaceutical manufacturing countries of the world. The Indian pharma industry

has shown a double-digit growth of around 15% led by growth of covid-19 products in the

last one year as against a single digit growth of 3% shown last year, according to the Indian

pharmaceutical market research company pharma Softech AWACS Pvt. Ltd.

The Indian pharma industry would close the year with a robust doble digit between 13% to

15%. The growth for the month November 21 has also been around 7%, which is also an

encouraging number, highlighted pharmaceutical market research company pharma Softech

AWACS Pvt. Ltd.

In the first half of 2021, we had a reasonable growth on account of covid related products like

remdesivir and vitamins and minerals kind of supplement products like Dolo 650 get boosted.

Doctor patient connect was less due to travel restrictions. This also led to much better hygiene

practices due to adoption of covid apt behaviour.

Pharma analyst also predict revival in the export market both from volume and pricing point

of view in 2022. New product launches will lead to revival and industry will grow at 10%+

growth rate in the financial year 2022.

15
According to the total sales audit data from world’s largest pharmaceutical market research

firm IMS health, the Indian pharma market (IPM) grew 59%yoy in April ,2021 vs 16%yoy in

march 2021 due to the low base effect in April, 2020and sharp surge in covid-19 related sales.

In covid-19 pandemic also had a significant impact on the Indian pharmaceutical industries.

The pandemic has both spurred and curtailed the growth of industry in different instance. In

some cases, it had led to growth in drug manufacturing backed by demand from the

government and the individuals alike for the drug that may be used in the treatment of covid-

19.

3.1.2 VISION

• To promote Indian pharma as the global leader for quality medicines and to ensure

availability accessibility and affordability of the drugs and medical devices in the

country.

• To enable Indian pharmaceuticals industry to play a leading role in the global market

and to ensure abundant availability, at reasonable prices within the country, of good

quality pharmaceuticals of mass consumption.

• To promote public-private partnership for development of pharmaceutical industry.

• To develop environmentally sustainable development of pharmaceutical industries.

• To become global healthcare organization and to be recognized as domestic and

internationally integrated healthcare and pharmaceutical company through

innovation.

3.1.3 MISSION

• Mission is to provide total customer satisfaction and achieve leadership in chosen

markets, products and services across the globe, through excellence in technology,

based on world-class research and development.

16
 • Improvement in community health and production of the best quality medicines are

some of the goals which they aspire to achieve with their business.

• To improve people lives through pharmacy practices innovation comprehensives

medications education, and inter-disciplinary clinical and practice research.

3.1.4 CHALLENGES

• Growing competition from generic pharmaceuticals, pharmaceutical fraud.

• Public and government pressure to make drug prices more affordable.

• Comparatively small domestic market size due to low medical and healthcare

expenditure in the country.

• Rising consumer expectations and difficulties manging brand health.

• Data breaches and other cybersecurity threats.

3.1.5 PRODUCT&SERVICES OF PHARMA INDUSTRY AND

ACHIVEMENTS

There are different types of pharmaceutical companies specialise in making different

pharmaceutical formulations. Additionally, these formulations all make use of different active

substances, fillers and additives. Therefore, hers a look at the most popular types of pharma

products that pharma business focus on.

• Oral drugs

• Parenteral formulations

• Topical medicines

• Modified release formulations

• Novel drugs formulations

• Oncological formulations

Following are the services provided by the pharmaceutical industry

1. Pharmaceutical development

17
 • Bio analysis services
• Supply chain services
• GMP AND CMS laboratory services
2. Manufacturing and packing
• On-site inspections
• Material science services • Equipment calibration
• Problem solving analysis
3. Support services
• Pharmaceutical and healthcare services
• Pharmaceutical auditing
• Regulatory and toxicology consultancy services
• Storage and distribution

3.1.6 ACHIVEMENTS
• Basket of medicines stock positioning
Product basket of BPPI comprises of around 1450 drugs and 204 surgical instruments.
• Coverage of the scheme 7018 PMBJP Kendra’s are functional across the country. The
priyojana has marked the presence in every district of India by
covering all the 734 districts of the country.

3.1.7 AWARDS
1. Leader category Award -------------- Cipla limited
2. Company of the year award------------- Micro labs
3. Start-up category Award--------------- vanguard diagnosis limited
4. Innovation category Award--------------Glenmark pharmaceuticals limited
5. CSR category Award----------------------Zydus life science limited

18
 3.2 COMPANY PROFILE

3.2.1 MICRO LABS LIMITED

Micro labs ltd was founded in 1973 by Late shri G.C Surana to manufacture ethical

pharmaceutical products with manufacturing facility in Chennai.

Micro labs limited is a multi-faceted healthcare organization with a proficient marketing

team, state of art of manufacturing facilities and R&D centres that are at with international

standard. All these backed by strong distribution network and path breaking research work

have placed us amongst India’s fast growing transitional healthcare organizations. We are in

to the manufacturing and marketing of pharmaceuticals products and APIs. Major products

are Dolo650, Amlong, lubrex, diapride, vildapride, Omlat, Avas, tripride, bactoclav,

Tenepride, and

arbitel.

The company is ranked 19th amongst all pharmaceutical companies in India as per AWACS

2021 retail audit and is ranked 14 th as per prescription audit by SMSRC 2021. Our brand

Dolo650 is ranked No 1 amongst all prescribed retail audit and is virtual a household names

across the country.

The company ethically promote its product to healthcare professionals across the country,

covering more than 150000 doctors. We have 14 manufacturing units across the country

dedicated to the manufactures of pharmaceuticals.

3.2.2 VISION

The company vision is built a desire to not just be the best, but a leader in the development,

manufacture, and sales of premium pharmaceutical products. We wish to raise the flag of

19
micro labs in India as well as abroad. Micro labs are to dedicate manufacturing tablets of the

high standards and marketing is at affordable price across the world.

3.2.3 ASPIRATION

The company aspiration to become an organization to the highest supported system. They

aspire to deliver value through high quality pharmaceutical products and built strong brand

across the medical segment. Our scientifically supported segment and strong implementation

capabilities can achieve this milestone.

3.2.4 BUSINESS BELIEFS

Micro labs are built around certain beliefs and ethics that placed us today where we are. A

frontrunner in the pharmaceutical industry. Their 4 pillars of business are

• Quality

• Ethics

• Customer focus

• Respect for people

Quality: A driving force for the organization across the value chain.

Ethics: To manage business by best practise of governance and ethics.

Customer focus: To understand customer needs and focus on total customer satisfaction.

Respect for the people: The companies most important aspect is to respect the people and

build relationship among us.

20
3.2.5 GLOBAL FOOTPRINTS OF MICRO LABS LIMITED

Micro labs have been in a continuous stage of growth ever since its founding years and

continue to chart its course as a leader in the pharmaceutical company. The company has

presence and hold over 50 countries with ground level operations in 25 countries. They are

poised have a quantum leap in global operation, with implementation of their growth

strategies. The micro labs company limited currently operates in various countries of Asia,

Europe, America and

Africa. They have already established a strong presence in USA, UK, Russia, Ukraine,

Nigeria, French, west Africa, east Africa, Myanmar, Philippines, Vietnam, Thailand, Sri

Lanka, and many more across the world.

3.2.6 MILE STONE

Micro labs are a multi-faceted organization with an annual turnover of Rs. 4083 crore

(20202021). The company had 14 oral formulation plants including an injectable unit, a bulk

drug facility, offices located oversees and strong distribution network. Their marketing efforts

span into 22 divisions with each division specialised to carter to various therapeutic segment.

The companies most important component however remains its 11790 dedicated employees.

Today the company has 22 marketing decisions catering to the leading therapeutic segments

as cardiology, diabetology, pain management, dermatology, veterinary, neurology, Etc.

3.2.7 THE DOLO REVELUTION

The phenomenal growth across specialities, Dolo-650 continuous to be the group’s crown

jewel, and much of that they thank to DOLOPAR, the tablet company began operations with.

21
By 1990, dipolar medicine become a household name. the Suranas try their hand at something

new, especially since the paracetamol new, especially since the paracetamol market had

become congested. In 1993, the company decided to launch Dolo-650, a successor to dipolar.

They launched Dolo-650, the paracetamol segment was crowded one. They wanted to

differentiate themselves, at that point, their medical advisor come and believed that they

should come out with 650milligram dose. Also unlike in cardiology or diabetology, where 50

brands come out at the same time with products, nobody bothered about the 650-milligram

market.

The most pharmaceutical companies brought out a 500-milligram tablet. Dolo650 was

intended to avoid an overdose of paracetamol tablets. They actually sell the concept of 650

milligram and aggressively ensure that the doctors prescribe. New product with different

combinations in 500-milligram segment were hitting the market. But there was nobody 650-

milligram in the market.

Since then, Dolo-650 has become the household product of the India and most was among the

most sought-after medicine during the COVID-19 crises. Until Covid happened not many

competitors had 650-milligram variant and this was only this time that they came with a

variant of 650-milligram and focused the segment.

As a result, the sales of the Dolo-650 doubled, forcing it id to start manufacturing Dolo-650

from 4 of its manufacturing facilities to meet the growing demand. The company has 17

manufacturing facilities across the country, with Dolo-650 being originally manufactured

originally from its Sikkim facility.

3.2.8 ACHIVEMENTS AND AWARDS

• Dolo 650 awarded as the Asia’s greatest brand 2016 by Asia one magazine and PwC
India.

22
 • Dolo brand was awarded as India’s most admired brand by white page international
• Dolo won brand of the year GOLD award.
• Micro labs Sikkim manufacturing unit bagged the prestigious silver award at India
manufacturing excellence award.

CHAPTER-4
DATA ANALYSIS AND
INTERPRETATION
[Link] ANALYSIS AND INTERPRETATON Sales
data of Dolo medicine during the year 2019
MONTHS SALES (‘0000)
Jan 7500
Feb 8200
Mar 11700
Apr 9500
May 6100
Jun 9900
Jul 5400
Aug 12200
Sep 10100
Oct 8900

23
 Nov 13900
Dec 14100
Calculation of linear trend for the following data:

MONTHS time period SALES ('0000) xy x^2

(x) (y)
Jan 1 7500 7500 1

Feb 2 8200 16400 4

Mar 3 11700 35100 9

Apr 4 9500 38000 16

May 5 6100 30500 25

Jun 6 9900 59400 36

Jul 7 5400 37800 49

Aug 8 12000 97600 64

Sep 9 10100 90900 81

Oct 10 8900 89000 100

Nov 11 13900 152900 121

Dec 12 14100 169200 144

70 117500 824300 650

Regression analysis
𝛴𝑥𝑦 𝑛𝑥̅𝑦̅
𝑏 and 𝑎 = 𝑦̅̅ -𝑏𝑥̅̅
̅

𝑥̅̅

𝑦̅̅

24
=

=
= 1040.

Now,

𝑎 = 𝑦̅̅ − 𝑏𝑥̅̅

= 9791 – 1040*(1.5)

= 9791-1560 =

8231.

Therefore, linear trend component for the sales of Dolo medicine during the year 2019 is

𝑦̅ = 8231 + 1040𝑥̅
The slope b=1040 indicates the over the past few months, the sale of Dolo had an average growth

about 10.40 crore.

• Linear trend for the sale of Dolo medicine during the year 2019

25
HYPOTHESIS:

H0: There is no significant difference in sales during pandemic

H1: There is significant sales during pandemic

Ha: µ, mu, = 10.40 crore.

Sale of Dolo medicine during the year 2020

MONTHS SALES (‘0000)
Jan 7500
Feb 8400
Mar 18200
Apr 13500
May 12500
Jun 16500
Jul 21000
Aug 25400
Sep 27900
Oct 25400
Nov 21800
Dec 17900

Calculation of linear trend for the following data:

26
 TIME PERIOD SALES ('0000)
MONTHS (x) (y) xy x^2
Jan 1 7500 7500 1
Feb 2 8400 16800 4
Mar 3 18200 54600 9
Apr 4 13500 54000 16
May 5 12500 62500 25
Jun 6 16500 99000 36
Jul 7 21000 147000 49
Aug 8 25400 203200 64
Sep 9 27900 251100 81
Oct 10 25400 254000 100
Nov 11 21800 239800 121
Dec 12 17900 214800 144
78 216000 1604300 650

Regression analysis

𝛴𝑥𝑦 𝑛𝑥̅𝑦̅
𝑏 and 𝑎 = 𝑦̅̅ − 𝑏𝑥̅̅
̅

𝑦̅̅

𝑏 650−12(42.9)

=
= 1472.

Now,

27
𝑎 = 𝑦̅̅ − 𝑏𝑥̅̅

= 18000 – 1472*(6.5)

= 18000-9568 = 8432.

Therefore, linear trend component for the sale of Dolo medicine during the year 2020 is y = 8431 +

1472𝑥̅

The slope b = 1472 indicates the over the past months, the sales of Dolo had an average growth

about 14.72 crore.

• Linear trend for the sale of Dolo medicine during the year 2020

HYPOTHESIS:

H0: There is no significant difference in sales during pandemic

H1: There is significant sales during pandemic

Ha: µ, mu, = 14.72 crore.

28
Sale of Dolo medicine during the year 2021
Months SALES (‘0000)
Jan 15900
Feb 16400
Mar 19400
Apr 48900
May 44200
Jun 20900
Jul 19900
Aug 40700
Sep 41000
Oct 34000
Nov 33400

29
 Dec 28900

Calculation of linear trend for the following data:

MONTHS TIME PERIOD SALES (‘0000) Xy x^2

(x) (y)
Jan 1 15900 15900 1
Feb 2 16400 32800 4
Mar 3 19400 58200 9
Apr 4 48900 195600 16
May 5 44200 221000 25
Jun 6 20900 125400 36
Jul 7 19900 139300 49
Aug 8 40700 325600 64
Sep 9 41000 369000 81
Oct 10 34000 340000 100
Nov 11 33400 367400 121
Dec 12 28900 346800 144
78 363600 2537000 650

Regression analysis
𝛴𝑥𝑦 𝑛𝑥̅𝑦̅
𝑏 and 𝑎 = 𝑦̅̅ − 𝑏𝑥̅̅
̅

𝑦̅̅
b
650−12(42.9)

=
= 1576

Now,

𝑎 = 𝑦̅̅ − 𝑏𝑥̅̅

30
= 30300 – 1576*(6.5)

= 30300-10244 = 20056.

Therefore, linear trend component for the sales of Dolo medicine during the year 2021 is y =
20056 + 1576𝑥̅

The slope b = 1576 indicates the over past few months, sale of the Dolo had high growth about 15.76

crore

• Linear trend for the sale of Dolo medicine during the year 2021

HYPOTHESIS:

H0: There is no significant difference in sales during pandemic

H1: There is significant sales during pandemic Ha:

µ, mu, = 15.76 crore.

31
Sale of Dolo medicine before the pandemic i.e., 2018-2019
MONTHS SALES (‘0000)
Jan 1000
Feb 800
Mar 1900
Apr 1230
May 1300
Jun 2400
Jul 1990
Aug 1300
Sep 1500
Oct 2531
Nov 200
Dec 184
Jan 7500
Feb 8200
Mar 8200
Apr 11700
May 9500
Jun 6100
July 9900
Aug 12200
Sep 10100
Oct 8900
Nov 13900
Dec 14100

32
Calculation of linear trend for the following table:
MONTHS TIME PERIOD SALES (‘0000) xy x^2
(x) (y)
Jan 1 1000 1000 1
Feb 2 800 1600 4
Mar 3 1900 5700 9
Apr 4 1230 4920 16
May 5 1300 6500 25
Jun 6 2400 14400 36
Jul 7 1990 13930 49
Aug 8 1300 10400 64
Sep 9 1500 13500 81
Oct 10 2531 25310 100
Nov 11 200 2200 121
Dec 12 184 2208 144
Jan 13 7500 97500 169
Feb 14 8200 114800 196
Mar 15 8200 123000 225
Apr 16 11700 187200 256
May 17 9500 161500 289
Jun 18 6100 109800 324
July 19 9900 188100 361
Aug 20 12200 244000 400
Sep 21 10100 212100 441
Oct 22 8900 195800 484
Nov 23 13900 319700 529
Dec 24 14100 338400 816
300 136635 2393568 5140

Regression analysis
𝛴𝑥𝑦−𝑛𝑥̅𝑦̅
𝑏= ∑ 𝑥2−𝑛(𝑥̅)2 and 𝑎 = 𝑦̅̅ − 𝑏𝑥̅̅

33
𝑥̅̅

𝑦̅̅
̅

𝑏 5140−24(156.2)

=
= 492.5

Now,

𝑎 = 𝑦̅̅ − 𝑏𝑥̅̅

= 5693 – 492.5*(12.5)

= 5693-6156 =460.

Therefore, linear trend component for the sales of Dolo medicine before pandemic i.e., 2018-

2019 is

y = -460 + 492𝑥̅

The slope indicates that over the past 2 years the sale of Dolo has no growth.

• Linear trend for the sale of Dolo medicine before the pandemic i.e., 2018-2019.

34
HYPOTHESIS:

H0: There is no significant difference in sales during pandemic H1: There is

significant sales during pandemic.

Ha: Null hypothesis.

35
Sales data of Dolo medicine after the pandemic i.e., 2020-2021
MONTHS SALES (‘0000)
Jan 7500
Feb 8400
Mar 18200
Apr 13500
May 12500
Jun 16500
Jul 21000
Aug 25400
Sep 27900
Oct 25400
Nov 21800
Dec 17900
Jan 15900
Feb 16400
Mar 19400
Apr 48900
May 44200
Jun 20900
Jul 19900
Aug 40700
Sep 41000
Oct 34000
Nov 33400
Dec 28900

36
Calculation of linear trend for the following Data:
MONTHS TIME PERIOD SALES (‘0000) Xy x^2
(y) (x)
Jan 1 7500 7500 1
Feb 2 8400 16800 4
Mar 3 18200 54600 9
Apr 4 13500 54000 16
May 5 12500 62500 25
Jun 6 16500 99000 36
Jul 7 21000 147000 49
Aug 8 25400 203200 64
Sep 9 27900 251100 81
Oct 10 25400 254000 100
Nov 11 21800 239800 121
Dec 12 17900 214800 144
Jan 13 15900 206700 169
Feb 14 16400 229600 196
Mar 15 19400 291000 225
Apr 16 48900 782400 256
May 17 44200 751400 289
Jun 18 20900 376200 324
Jul 19 19900 378100 361
Aug 20 40700 814000 400
Sep 21 41000 861000 441
Oct 22 34000 748000 484
Nov 23 33400 768200 529
Dec 24 28900 693600 816
300 579600 8504500 5140

Regression analysis:

37
 𝛴𝑥𝑦 𝑛𝑥̅𝑦̅
𝑏 and 𝑎 = 𝑦̅̅ − 𝑏𝑥̅̅
̅

𝑥̅̅

𝑦̅̅
̅

𝑏 5140−24(156.2)

=
= 904.8

Now,

𝑎 = 𝑦̅̅ − 𝑏𝑥̅̅

= 24150 – 904.8*(12.5)

= 24150-11310 = 12840.

Therefore, linear trend component for the sale Dolo medicine after the pandemic i.e., 2020-

2021

y = 12840 + 904.8𝑥̅

The slope b = 904.8 indicates the sale after the pandemic had a maximum growth about

90.4 crore.

• Liner trend for the sale of Dolo medicine after the pandemic i.e., 2020-2021

38
HYPOTHESIS:

H0: There is no significant difference in sales during pandemic

H1: There is significant sales during pandemic Ha: µ, mu, =
90.4 crore.

CHAPTER-5 FINDINGS,
CONCLUSIONS AND SUGGESTIONS

FINDINGS
The Dolo 650 is the currently the second most popular anti fever and analgesic tablet in India

with turnover of Rs 3.1 billion in 2021, and become the market leader.

1. From the study it is found that the sale of Dolo medicine before pandemic in the year

39
 2018 there was an average growth of 5.26 crore.

2. In the year 2019 before pandemic the sale of Dolo medicine had an average growth of

10.40 crore.

3. The study found that sale of Dolo medicine after pandemic in the year 2020 had

topped the charts of sale of paracetamol increases to 14.70 crore.

4. In the year 2021 Dolo, which is currently the most prescribed fever medicine for

covid-19 patients, and had a high growth of monthly sale to 15.76 crore and had an

annual turnover of Rs 307 crore in 2021.

5. By comparing the sale of Dolo medicine 24 months before pandemic and 24 months

after pandemic, study found that before covid-19 there is an average sale and had no

growth of Dolo medicine.

6. After covid-19 there is a maximum sales growth of 90.4 crore.

CONCLUSION
A study on sales forecast of dolo medicine before and after covid-19 is focus on analyzing the

sales of Dollo medicine during the pandemic and become the market leader.

To conclude with the study, it is found that the total revenue generated by Dolo increased by

289.6 per cent between the second quarter of 2020 and the second quarter of 2021. As India is

suffering from covid-19, Dolo which has clocked sales of Rs 5.7 billion during pandemic

since march 2020 and topped the chart of paracetamol pill, and been said as “favorite snack

of India.

Dolo is currently the second most popular anti-fever and analgesic tablet in India, with

turnover of 3.1 billion in [Link] just in terms of sales, Dolo also become the Most-googled

medicine in the country. In fact, Dolo was the most searched keyword in google, with around

2 lakh searches since the COVID outbreak.

40
From the research Dolo is termed as one stop solution for everything like fever, body ache,

cold, headache.

SUGGESTIONS
1. Proper control over various may increase the profits of a company.

2. To purchase raw material at lower cost will reduce the cost of material

3. The company has to give importance to maintenance and consumption of raw material

which would otherwise result in the overstocking and leads to obsolesce

4. In order to overcome the expenses, the firm reduce the operating expenses labor cost,

material cost and other overheads are reduced so as to improve the profitability of the

company.

41
 BIBILOGRAPHY
• [Link]

• [Link]

asuperbrand/.cms

• [Link]

2022-01-22

• [Link]

7746805/lite/

• [Link]

omicorninfection-zoom-so-does-dolos-market-share/amp_articleshow/[Link]

• [Link]

dolo-tablets-33363

• [Link]

sales-brand-story-1293163243-html

• [Link]

• [Link]

• [Link]

• [Link]

42